Clinical Trial Update: Pelacarsen Roll-over Extension Program [Phase 3]

View source ↗

Summary

This clinical trial update indicates a roll-over extension program for pelacarsen in Phase 3 for atherosclerotic cardiovascular disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Pelacarsen (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Cardiovascular Disease | Phase 3 | Status: RECRUITING